Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) yesterday and set a price target of $12. The company’s shares closed on Friday at $5.22.
Olson commented:
“TXMD signed a deal bringing a third asset into its rapidly growing portfolio of differentiated women’s health products. TXMD has licensed exclusive US rights to commercialize a one-year vaginal hormonal system for contraception. This innovative product combines a novel progestin, Nesterone, with estrogen to prevent ovulation for an entire year, thus providing women with long-term yet reversible control over their fertility. This form of contraception represents a growing opportunity as demonstrated by the commercial success of Nuvaring with US sales of $576M in 2017. TXMD owes milestone payments of $20M assuming FDA approval (Aug. ’17 the first commercial batch of the product. Although not in our model, we view this deal as highly accretive.”
According to TipRanks.com, Olson has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.3% and a 38.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $17.25 average price target, which is a 230.5% upside from current levels. In a report issued on July 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $26 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $4.34. Currently, TherapeuticsMD has an average volume of 3.25M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
